The California Institute for Regenerative Medicine (CIRM) governing board approved $8.5 million to support two important programs.
The funding will continue the Summer Program to Accelerate Regenerative Medicine Knowledge (SPARK) and the Alpha Stem Cell Clinics (ASCC) Network. Together, these programs help prepare future scientists and advance stem cell and gene therapy clinical trials.
SPARK Supports the Next Generation
In February, the board approved continued funding for stem cell education programs. Those programs serve undergraduate, master’s, doctoral, postdoctoral, and medical students.
SPARK supports high school students through summer research internships. The program gives students hands-on experience in stem cell biology, gene therapy, and regenerative medicine.
The board approved $5.1 million for 10 new SPARK awards. Each award will provide up to $509,000 over five years.
Together, the awards will support 500 trainees across California. Students will conduct summer research at participating institutions.
SPARK aims to prepare and inspire the next generation of scientists. The program also expands access for California’s diverse population.
Many students cannot pursue summer research because of financial barriers. SPARK helps reduce those barriers and opens doors to students from underserved communities.
ASCC Network Strengthens Clinical Trials
The ASCC Network connects five California medical centers. Each site specializes in accelerating stem cell and gene therapy clinical trials.
The centers share resources and expertise. They also coordinate activities to improve efficiency and increase the likelihood of successful trials.
The network has supported more than 105 trials across multiple disease areas.
CIRM plans to expand the ASCC Network next year. However, funding for the five current sites has ended or will soon reach the end of its award period.
The board approved $3.4 million in supplemental funding to maintain the network. Five awards of up to $680,000 will support the participating sites.
Each host institution must match its CIRM award.
The funds will help sites retain staff and continue essential operations. These activities include coordinating clinical research and responding to patient and public inquiries.
Investing in Research and Infrastructure
CIRM President and CEO Maria T. Millan, M.D., emphasized the importance of both programs.
“Education and infrastructure are two funding pillars critical for creating the next generation of researchers and conducting stem cell-based clinical trials,” Millan said.
Proposition 14 recognized the importance of these programs. CIRM expects education and clinical infrastructure to remain central to its strategy.
The board also awarded $14.5 million for three translational-stage research projects through the TRAN1 program. These awards support early development activities needed to advance potential therapies toward clinical studies or broader use.
The table below summarizes the awards.
| Application | Title | Institution | Award |
| TRAN1-12245 | Development of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma | UCSF | $2,663,144 |
| TRAN1-12258 | CAR-Tnm cell therapy for melanoma targeting TYRP-1 | UCLA | $5,904,462 |
| TRAN1-12250 | HSC-Engineered Off-The-Shelf CAR-iNKT Cell Therapy for Multiple Myeloma | UCLA | $5,949,651 |

Dear Sir,Do you have any idea or who is doing stem therapy for macular degeneration with newborn stem cells? Shirley Treat931-201-0969 davetreat@yahoo.com
Hello David, the only research i know for macular degeneration is this one: https://clinicaltrials.gov/ct2/show/NCT04339764 I hope that helps.